Skip to main content
OpenTrials
Completed

NCT Number: NCT02076711

Myocardial Efficiency of the Left Ventricle in Asymptomatic Patients With Aortic Valve Stenosis - a Prognostic Marker and a Target for Intervention?

Background - Aortic valve stenosis (AS) is the most common heart valve disease among adults in the Western world with a prevalence of 3 % in people older than 75 years of age. AS usually deteriorates over time leading to heart failure, with high mortality if aortic valve replacement (AVR) is not performed. Thus optimal timing of AVR is crucial, but can be challenging. Increasing life expectancy in our society will augment the therapeutic and socio economic impact of AS disease on our health care system. Therefore, new techniques for monitoring asymptomatic AS patients are needed. A potential approach is monitoring of LV myocardial efficiency (mechanical work/oxygen consumption). These measures have been suggested to be involved in the progression of non-valvular heart failure and closely related to prognosis, but never applied in a larger population of patients with AS. At present there are no recognized pharmacological treatments of AS. It is known that beta-blocker treatment in non-valvular systolic heart failure reduce heart rate, improves LV myocardial efficiency and reduces mortality. However, in patients with AS, the effects of beta-blockers are unknown.

Hypotheses - Treatment with the beta-blocker metoprolol succinate in patients with asymptomatic moderate to severe AS has beneficial effects on LV myocardial oxidative metabolism, myocardial efficiency and contractile function.

Objectives - To investigate if beta-blocker treatment in patients with moderate to severe, asymptomatic AS has beneficial effects on LV myocardial efficiency, contractile function and physical performance.

Design - A randomized double blind placebo controlled intervention trial. 40 patients with asymptomatic AS will be randomized to either per oral metoprolol succinate (N = 20) or placebo (N= 20) for 22 weeks.

Primary objective - Changes in myocardial efficiency

Secondary objectives - Myocardial oxygen consumption, Myocardial perfusion at rest, LV myocardial function, LVmass, Aortic valve area and transaortic valve velocities, 6 minute walking distance, N-terminal prohormone of brain natriuretic peptide, Quality of life (estimated by Minnesota living with heart failure questionnaire), LV wall stress

Methods - Patients will undergo echocardiography (resting and exercise), [11C]acetate PET and cardiac magnetic resonance imaging.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Aortic Stenosis Aortic Valve Disease Aortic Valve Stenosis Cardiovascular Diseases Heart Diseases Heart Valve Diseases Ventricular Outflow Obstruction

Age range

20 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 2

Primary location

Aarhus University Hospital, Department of Cardiology, Brendstrupgaardsvej 100

Aarhus N, 8200, Denmark

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Aortic valve area ≤1,2 cm2 and/or transaortic maximal velocity (VmaxAO) of 3,0-5,0 m/s
  • Sinus rhythm >60/min after 5 minutes of rest
  • LVEF >≥50%
  • Male or female
  • Age 20-100 years old
  • Safe birth control management for women of childbearing potential.
  • Negative urine-HCG for women of childbearing potential
  • Ability to understand the written patient information and to give informed consent

Exclusion criteria

  • Systolic BP <100 mmHg after 5 minutes of rest
  • Left ventricular posterior wall thickness >17 mm
  • Signs or history of major myocardial infarction and/or severe ischemic heart disease
  • Severe asthma or chronic obstructive pulmonary disease
  • New York Heart Association (NYHA) classification > I due to AS
  • NYHA > II due to non-cardiac causes
  • 2ᵒ or 3ᵒ atrioventricular block
  • Ongoing beta-blocker therapy
  • Ongoing verapamil or diltiazem therapy
  • Ongoing monoamine oxidase inhibitors therapy (except MAO-B-inhibitors)
  • Sick sinus syndrome
  • Atrial fibrillation or fluttering
  • Lack of stable sinus rhythm
  • Pheochromocytoma
  • Severe peripheral vascular disease
  • Intolerance of Metoprolol succinate or its excipients
  • Other disease or treatment making subject unsuitable for study participation
  • Intolerance of tracer used for [11C]acetate PET recordings
  • Participation in other intervention study

Treatment and study plan

Metoprololsuccinate

Drug

Placebo

Drug

Placebo

Primary outcomes

  1. LV myocardial efficiency

    Time frame: Changes will be evaluated after an expected average of 22 weeks of treatment

Secondary outcomes

  1. LV oxygen consumption

    Time frame: Changes will be evaluated after an expected average of 22 weeks of treatment

  2. LV perfusion

    Time frame: Changes will be evaluated after an expected average of 22 weeks of treatment

  3. LV myocardial function

    Time frame: Changes will be evaluated after an expected average of 22 weeks of treatment

  4. LVmass

    Time frame: Changes will be evaluated after an expected average of 22 weeks of treatment

  5. Aortic valve area

    Time frame: Changes will be evaluated after an expected average of 22 weeks of treatment

  6. Transaortic valve velocities

    Time frame: Changes will be evaluated after an expected average of 22 weeks of treatment

  7. 6 minute walking distance

    Time frame: Changes will be evaluated after an expected average of 22 weeks of treatment

  8. N-terminal prohormone of brain natriuretic peptide

    Time frame: Changes will be evaluated after an expected average of 22 weeks of treatment

  9. Quality of life - estimated by Minnesota living with heart failure questionnaire

    Time frame: Changes will be evaluated after an expected average of 22 weeks of treatment

  10. LV wall stress

    Time frame: Changes will be evaluated after an expected average of 22 weeks of treatment

Sponsors and collaborators

Lead sponsor

Aarhus University Hospital

Other

Registry information

Acronym: MELVAS

Important dates

Study start
2013
Primary completion
2015
Study completion
2015
First posted
Mar 4, 2014
Registry last updated
Nov 11, 2015

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.